Loading
CDH6 is an adhesion protein from kidney development that reappears on ovarian and kidney cancers.
Cadherin-6 (CDH6) is a type II cadherin and a fetal kidney marker that is overexpressed in ovarian cancer and renal cell carcinoma with low normal adult expression, the profile an ADC target needs. It is found in 65-85% of ovarian cancers, particularly high-grade serous, and 60-80% of renal cell carcinomas by IHC. Raludotatug deruxtecan (R-DXd), a CDH6 ADC with the DXd payload, is in phase 3 in platinum-resistant ovarian cancer (REJOICE-Ovarian01). The main open question is whether the DXd payload's interstitial lung disease signal and the expression threshold for benefit will hold up in a randomised setting. The simple version is an adhesion protein from kidney development that reappears on ovarian and kidney cancers, giving an ADC a clean address.
In plain words · CDH6 is an adhesion protein from kidney development that reappears on ovarian and kidney cancers.
CDH6 is an adhesion protein from kidney development that reappears on ovarian and kidney cancers.
CDH6 is a type II cadherin and a fetal kidney marker.
1 product aims at CDH6: antibody-drug conjugates. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Phase 2/3 for the CDH6 ADC. Timing is a registry-based estimate. Source
Tumour-associated overexpression: 1 cell-killing or cell-finding medicine (Raludotatug deruxtecan) aim at the antigen, which HPA finds stained high in 2 normal tissues; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA CDH6: RNA tissue enhanced (blood vessel 12 nTPM, kidney 14 nTPM); high antibody staining in 2 normal tissues; highest cancer staining renal cancer (1 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Renal cell carcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas CDH6 tissue; Human Protein Atlas CDH6 pathology; Open Targets ENSG00000113361 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Suzuki et al, Cell Regul, 1991, "Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue". Source.
CDH6 is a type II cadherin and a fetal kidney marker.
RNA: tissue enhanced (blood vessel 12 nTPM, kidney 14 nTPM), detected in many normal tissues.
Medium: Cerebellum, Cerebral cortex, Cervix, Endometrium, Fallopian tube, Heart muscle, Hippocampus, Liver.
RNA group enriched: Kidney Renal Clear Cell Carcinoma 64 pTPM, Kidney Renal Papillary Cell Carcinoma 80 pTPM, Ovary Serous Cystadenocarcinoma 34 pTPM.
Medium only: ovarian cancer, pancreatic cancer, stomach cancer, thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Ovarian cancer | 65-85% | IHC, any expression | High-grade serous | Wikipedia |
| Renal cell carcinoma | 60-80% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Raludotatug deruxtecan is a CDH6 ADC in phase 3 for platinum-resistant ovarian cancer.
Query for this target: (TITLE:"CDH6" OR ABSTRACT:"CDH6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDH6, not a curated reading list.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC), Ovarian cancer and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.